Growth Metrics

Iovance Biotherapeutics (IOVA) EBIT (2016 - 2025)

Historic EBIT for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' EBIT fell 655.13% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 313.66%. This contributed to the annual value of -$395.3 million for FY2024, which is 1417.43% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported EBIT of -$94.9 million as of Q3 2025, which was down 655.13% from -$113.8 million recorded in Q2 2025.
  • Iovance Biotherapeutics' EBIT's 5-year high stood at -$86.6 million during Q4 2024, with a 5-year trough of -$121.3 million in Q4 2023.
  • For the 3-year period, Iovance Biotherapeutics' EBIT averaged around -$107.8 million, with its median value being -$110.9 million (2023).
  • In the last 5 years, Iovance Biotherapeutics' EBIT skyrocketed by 2860.06% in 2024 and then plummeted by 1163.73% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' EBIT (Quarter) stood at -$121.3 million in 2023, then rose by 28.6% to -$86.6 million in 2024, then fell by 9.62% to -$94.9 million in 2025.
  • Its EBIT stands at -$94.9 million for Q3 2025, versus -$113.8 million for Q2 2025 and -$121.2 million for Q1 2025.